We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INDUSTRY: FDA MOVING TOWARD NEW CGMP APPROACH, GREATER USE OF INTERNATIONAL STANDARDS

INDUSTRY: FDA MOVING TOWARD NEW CGMP APPROACH, GREATER USE OF INTERNATIONAL STANDARDS

June 5, 2006

The FDA's decision to withdraw seven guidances as inconsistent with its pharmaceutical current good manufacturing practices (cGMP) initiative is a sign that the agency is serious about updating its approach to cGMP and taking a more global view of regulations, industry sources say.

The agency withdrew several Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research guidances because of inconsistencies with its Pharmaceutical Current Good Manufacturing Practices for the 21st Century initiative. In the meantime, the FDA is recommending that the drug industry use International Conference on Harmonisation (ICH) documents as a guide to manufacturing practices.

The move is being lauded by industry sources that say the agency's previous manufacturing standards had focused too little on risk-based decisionmaking.

The agency's approach to GMP had been "overly prescriptive," representing "overkill in a check-the-box mentality," Janeen Skutnik, Pfizer's director of compendia affairs and regulatory monitoring, told FDAnews.

The agency's suggestion for industry to use ICH documents is also another sign that the FDA is moving toward a global approach to regulation, Skutnik said.

But companies will face short-term compliance problems through the agency's actions, Gordon Richman, vice president of strategic compliance and general counsel of the consulting firm EduQuest, said.

Industry faces a learning curve for two reasons, Richman said. First, the move from a quality assurance approach to the FDA's new quality systems approach is an "evolutionary step" in risk management, requiring significant infrastructure changes for companies.

For example, the FDA now expects company management to be more involved in ensuring proper manufacturing practices. Industry needs to change their infrastructure to ensure this greater involvement, Richman said.

Some companies are "mistakenly sitting back" waiting for amendments to the cGMP regulations before taking steps to comply with the initiative, he said. (http://www.fdanews.com/did/5_108/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Updates Smiths Medical CADD System Recall to Class I

  • Eisai’s New Alzheimer’s Drug Leqembi Hits the U.S. Market

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing